27913319|t|Assessing the benefits of targeted drug delivery by nanocarriers: A partico/pharmacokinetic framework
27913319|a|An in vivo kinetic framework is introduced to analyze and predict the quantitative advantage of using nanocarriers to deliver drugs, especially anticancer agents, compared to administering the same drugs in their free form. This framework recognizes three levels of kinetics. First is the particokinetics associated with deposition of nanocarriers into tissues associated with drug effect and toxicity, their residence inside those tissues, and elimination of the nanocarriers from the body. Second is the release pattern in time of free drug from the nanocarriers. Third is the pharmacokinetics of free drug, as it relates to deposition and elimination processes in the target and toxicity associated tissues, and total body clearance. A figure of merit, the drug targeting index (DTI), is used to quantitate the benefit of nanocarrier based drug delivery by considering the effects of preferential deposition of nanoparticles into target tissues and relative avoidance of tissues associated with drug toxicity, compared to drug that is administered in its free form. General methods are derived for calculating DTI when appropriate particokinetic, pharmacokinetic, and drug release rate information is available, and it is shown that relatively simple algebraic forms result when some common assumptions are made. This approach may find use in developing and selecting nanocarrier formulations, either for populations or for individuals.
27913319	14	22	benefits	T081	C0814225
27913319	26	34	targeted	T169	C1521840
27913319	35	48	drug delivery	T074	C0085104
27913319	52	64	nanocarriers	T073	C1450053
27913319	68	101	partico/pharmacokinetic framework	T169	C0031328
27913319	105	112	in vivo	T082	C1515655
27913319	113	130	kinetic framework	T169	C0031328
27913319	148	155	analyze	T062	C0936012
27913319	172	184	quantitative	T081	C0392762
27913319	204	216	nanocarriers	T073	C1450053
27913319	220	233	deliver drugs	T074	C0085104
27913319	246	263	anticancer agents	T109,T121	C0003392
27913319	265	273	compared	T052	C1707455
27913319	277	290	administering	T061	C1533734
27913319	300	305	drugs	T121	C0013227
27913319	331	340	framework	T078	C0178566
27913319	358	364	levels	T080	C0441889
27913319	368	376	kinetics	T039	C0031327
27913319	391	406	particokinetics	T070	C0022702
27913319	407	422	associated with	T080	C0332281
27913319	423	433	deposition	T169	C0333562
27913319	437	449	nanocarriers	T073	C1450053
27913319	455	462	tissues	T024	C0040300
27913319	463	478	associated with	T080	C0332281
27913319	479	490	drug effect	T169	C0728866
27913319	495	503	toxicity	T037	C0600688
27913319	511	520	residence	T082	C0237096
27913319	534	541	tissues	T024	C0040300
27913319	547	558	elimination	T040	C0683141
27913319	566	578	nanocarriers	T073	C1450053
27913319	588	592	body	T016	C0242821
27913319	608	623	release pattern	T033	C0231360
27913319	635	644	free drug	T081	C0678752
27913319	654	666	nanocarriers	T073	C1450053
27913319	681	697	pharmacokinetics	T039	C0031327
27913319	701	710	free drug	T081	C0678752
27913319	729	739	deposition	T169	C0333562
27913319	744	765	elimination processes	T040	C0683141
27913319	773	779	target	T169	C1521840
27913319	784	792	toxicity	T037	C0600688
27913319	793	803	associated	T080	C0439849
27913319	804	811	tissues	T024	C0040300
27913319	817	837	total body clearance	T034	C0087101
27913319	862	882	drug targeting index	T081	C1637833
27913319	884	887	DTI	T081	C1637833
27913319	901	911	quantitate	T081	C0392762
27913319	927	938	nanocarrier	T073	C1450053
27913319	945	958	drug delivery	T074	C0085104
27913319	978	985	effects	T080	C1280500
27913319	1002	1012	deposition	T169	C0333562
27913319	1016	1029	nanoparticles	T073	C1450054
27913319	1035	1041	target	T169	C1521840
27913319	1042	1049	tissues	T024	C0040300
27913319	1076	1083	tissues	T024	C0040300
27913319	1084	1099	associated with	T080	C0332281
27913319	1100	1113	drug toxicity	T037	C0013221
27913319	1115	1123	compared	T052	C1707455
27913319	1127	1131	drug	T121	C0013227
27913319	1140	1152	administered	T061	C1533734
27913319	1179	1186	methods	T170	C0025663
27913319	1203	1214	calculating	T052	C1441506
27913319	1215	1218	DTI	T081	C1637833
27913319	1236	1250	particokinetic	T070	C0022702
27913319	1252	1267	pharmacokinetic	T169	C0031328
27913319	1273	1290	drug release rate	T081	C1521828
27913319	1372	1378	result	T169	C1274040
27913319	1448	1458	developing	T091	C0872152
27913319	1473	1484	nanocarrier	T073	C1450053
27913319	1485	1497	formulations	T077	C1705957
27913319	1510	1521	populations	T098	C1257890
27913319	1529	1540	individuals	T098	C0237401